NASH and Nutritional Therapy 2005
DOI: 10.1007/4-431-27172-4_1
|View full text |Cite
|
Sign up to set email alerts
|

Nonalcoholic Fatty Liver (NAFL): Overview

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2012
2012
2012
2012

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 281 publications
0
2
0
Order By: Relevance
“…Parenteral administration of therapeutic doses of quinidine and quinine caused forearm vasodilatation and decreased mean arterial blood pressure Bateman & Dyson, 1986;Nappi & Mason, 1990;Mariano et al, 1992). It has been known for over 60 years that quinine and quinidine can attenuate vasoconstrictor responses to sympathetic nerve stimulation and regional noradrenaline (NA) infusion, effects consistent with their postjunctional a-adrenoceptor antagonistic properties (Nelson, 1928;Hiatt, 1950;Schmid et al, 1974;Mecca et al, 1980;Caldwell et al, 1983). In rat cardiac membranes, human platelets and rat kidney, quinidine is a competitive antagonist at oel-and a2-receptors, but it is substantially more potent in antagonizing aj-than X2-adrenoceptors (Motulsky et al, 1984).…”
Section: Introductionmentioning
confidence: 99%
“…Parenteral administration of therapeutic doses of quinidine and quinine caused forearm vasodilatation and decreased mean arterial blood pressure Bateman & Dyson, 1986;Nappi & Mason, 1990;Mariano et al, 1992). It has been known for over 60 years that quinine and quinidine can attenuate vasoconstrictor responses to sympathetic nerve stimulation and regional noradrenaline (NA) infusion, effects consistent with their postjunctional a-adrenoceptor antagonistic properties (Nelson, 1928;Hiatt, 1950;Schmid et al, 1974;Mecca et al, 1980;Caldwell et al, 1983). In rat cardiac membranes, human platelets and rat kidney, quinidine is a competitive antagonist at oel-and a2-receptors, but it is substantially more potent in antagonizing aj-than X2-adrenoceptors (Motulsky et al, 1984).…”
Section: Introductionmentioning
confidence: 99%
“…We were the first to reported on the role for platelet derived growth factor (PDGF) in experimental models of hepatic fibrosis [8,9] and we showed that PTX blocked fibrosis via an effect on PDGF and that this occurred by blocking phosphorylation of c-jun on serine 73 [10]. We began investigations of non alcoholic steatohepatitis (NASH) mediated fibrosis [11,12] and reported that ribavirin but not interferon inhibited fibrosis also associated with HCV and that this effect was mediated by the block of phosphorylation of c-jun on ser 73 and resulted in decreased synthesis of collagen and hepatic stellate cell (HSC) proliferation [13]. We reported that PTX decreased NASH sera-stimulated FSI (our patented diagnostic test for fibrosis using HSCs as the target cell) and c-Jun phosphorylation as assessed by 3 H-thymidine incorporation and Western analysis respectively, such that NASH patient sera stimulated HSC proliferation and increased phosphorylated c-Jun in HSCs and that PTX significantly decreased NASH patient sera stimulated HSC proliferation and decreased NASH sera-stimulated phosphorylated c-Jun in HSCs [14].…”
mentioning
confidence: 99%